8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Nov 12, 2025·SEC
Bolt Biotherapeutics, Inc.(BOLT)Earnings, Financials & Key Ratios
BOLT•NASDAQ
$4.05
Price updated Jul 7, 2026
AboutBolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.Show more
- Revenue$8M
- EBITDA-$33M+53.5%
- Net Income-$33M+47.1%
- EPS (Diluted)-17.85-981.8%
- Gross Margin80.62%-19.4%
- EBITDA Margin-430.7%+53.5%
- Operating Margin-450.07%+52.6%
- Net Margin-433.74%+47.2%
- ROE-79.75%-7.4%
BOLT Price & Volume
Bolt Biotherapeutics, Inc. (BOLT) stock price & volume — 10-year historical chart
Loading chart...
Severe Liquidity Constraints Threaten Clinical Development Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical liquidity and dilution
Key Thesis Takeaways
- Bolt Biotherapeutics faces a precarious financial outlook characterized by a rapid depletion of its asset base, which has fallen from $159.8 million in 2023Q4 to $48.0 million in 2026Q1.
- The company's reliance on lumpy, non-recurring milestone payments has failed to provide a sustainable revenue stream, leaving it highly vulnerable to capital market volatility.
- Investors should remain cautious as the firm's inability to achieve operating leverage, evidenced by a -292.3% operating margin in 2026Q1, necessitates urgent and potentially dilutive financing to maintain its clinical pipeline.
Verdict Logic
the company's critical liquidity risk is underscored by a cash position of only $11.6 million against a history of consistent quarterly losses and an eroding equity base that has dropped to $19.8 million.
BOLT Growth Metrics
Bolt Biotherapeutics, Inc. (BOLT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years101.61%
3 Years10.33%
TTM78.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM53.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-851.5%
Return on Capital
10 Years-74.07%
5 Years-51.34%
3 Years-54.07%
Last Year-52.44%
BOLT Recent Earnings
Bolt Biotherapeutics, Inc. (BOLT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$4.31-51.2%
$2.85
Rev
$26,000-98.3%
$2M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$3.84+10.7%
$4.30
Rev
$3M+275.0%
$666,667
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$3.72+26.6%
$5.07
Rev
$2M+164.3%
$820,800
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$4.46+30.3%
$6.40
Rev
$2M+113.3%
$845,800
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $4.31vs $2.85-51.2% | $26,000vs $2M-98.3% |
| Q2 2026 | Mar 12, 2026 | $3.84vs $4.30+10.7% | $3Mvs $666,667+275.0% |
| Q4 2025 | Nov 12, 2025 | $3.72vs $5.07+26.6% | $2Mvs $820,800+164.3% |
| Q3 2025 | Aug 14, 2025 | $4.46vs $6.40+30.3% | $2Mvs $845,800+113.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Bolt Biotherapeutics, Inc. (BOLT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.05 | $7.78M | -0.23 | 0.07% | -433.74% | -79.75% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $23.24 | $2.05B | -7.06 | 627.84% | -112.01% | -256.66% | — |
Compare BOLT vs Peers
Bolt Biotherapeutics, Inc. (BOLT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BOLT SEC Filings & Documents
Bolt Biotherapeutics, Inc. (BOLT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BOLT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BOLT Frequently Asked Questions
Bolt Biotherapeutics, Inc. (BOLT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Bolt Biotherapeutics, Inc.'s revenue?
Bolt Biotherapeutics, Inc. (BOLT) reported $6.5M in revenue for fiscal year 2025.
How fast is Bolt Biotherapeutics, Inc. growing?
Bolt Biotherapeutics, Inc. (BOLT) grew revenue by 0.1% over the past year. Growth has been modest.
Is BOLT profitable?
Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $29.6M for fiscal year 2025.
Dividend & Returns
What is BOLT's return on equity?
Bolt Biotherapeutics, Inc. (BOLT) has a return on equity (ROE) of -79.7%. Negative ROE indicates the company is unprofitable.
What is Bolt Biotherapeutics, Inc.'s free cash flow?
Bolt Biotherapeutics, Inc. (BOLT) had negative free cash flow of $26.6M in fiscal year 2025, likely due to heavy capital investments.